Biolife Solutions (BLFS) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
82.3M
Gross Profit
53.7M
65.25%
Operating Income
-7.1M
-8.67%
Net Income
-20.2M
-24.54%
EPS (Diluted)
-$0.44
Balance Sheet Metrics
Total Assets
399.5M
Total Liabilities
50.6M
Shareholders Equity
348.9M
Debt to Equity
0.14
Cash Flow Metrics
Operating Cash Flow
16.9M
Free Cash Flow
4.9M
Revenue & Profitability Trend
Biolife Solutions Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 82.3M | 143.3M | 161.8M | 119.2M | 48.1M |
| Cost of Goods Sold | 28.6M | 96.5M | 107.9M | 82.1M | 20.6M |
| Gross Profit | 53.7M | 46.8M | 53.8M | 37.0M | 27.4M |
| Operating Expenses | 58.1M | 99.1M | 84.0M | 59.5M | 28.4M |
| Operating Income | -7.1M | -57.5M | -39.9M | -30.6M | -4.0M |
| Pre-tax Income | -11.4M | -66.3M | -144.8M | -29.0M | -1.3M |
| Income Tax | -38.0K | 169.0K | -5.0M | -20.1M | -3.3M |
| Net Income | -20.2M | -66.4M | -139.8M | -8.9M | 2.0M |
| EPS (Diluted) | -$0.44 | -$1.52 | -$3.29 | -$0.22 | $0.03 |
Income Statement Trend
Biolife Solutions Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 148.8M | 120.6M | 138.5M | 126.1M | 114.7M |
| Non-Current Assets | 250.7M | 292.1M | 311.8M | 428.2M | 120.1M |
| Total Assets | 399.5M | 412.7M | 450.2M | 554.3M | 234.8M |
| Liabilities | |||||
| Current Liabilities | 32.7M | 42.2M | 44.6M | 42.7M | 15.6M |
| Non-Current Liabilities | 17.8M | 32.9M | 41.5M | 33.5M | 14.0M |
| Total Liabilities | 50.6M | 75.1M | 86.0M | 76.2M | 29.6M |
| Equity | |||||
| Total Shareholders Equity | 348.9M | 337.7M | 364.2M | 478.0M | 205.2M |
Balance Sheet Composition
Biolife Solutions Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -20.2M | -66.4M | -139.8M | -8.9M | 2.0M |
| Operating Cash Flow | 16.9M | -31.4M | -122.6M | -5.7M | 9.7M |
| Investing Activities | |||||
| Capital Expenditures | -3.2M | -6.4M | -10.4M | -8.4M | -4.6M |
| Investing Cash Flow | 58.6M | 17.8M | -58.1M | -13.2M | -24.7M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -7.0M | 10.1M | 16.0M | -35.7M | 100.6M |
| Free Cash Flow | 4.9M | -18.9M | -18.9M | -13.0M | 2.0M |
Cash Flow Trend
Biolife Solutions Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-50.75
Forward P/E
-80.54
Price to Book
3.04
Price to Sales
12.22
PEG Ratio
-80.54
Profitability Ratios
Profit Margin
-11.86%
Operating Margin
-5.09%
Return on Equity
-2.52%
Return on Assets
-0.79%
Financial Health
Current Ratio
4.73
Debt to Equity
7.64
Beta
1.82
Per Share Data
EPS (TTM)
-$0.19
Book Value per Share
$7.42
Revenue per Share
$1.89
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| blfs | 1.1B | -50.75 | 3.04 | -2.52% | -11.86% | 7.64 |
| Intuitive Surgical | 189.7B | 77.39 | 11.09 | 15.96% | 28.41% | 0.00 |
| Becton, Dickinson | 50.0B | 33.87 | 1.98 | 5.89% | 7.18% | 76.34 |
| Lemaitre Vascular | 1.9B | 42.77 | 5.48 | 13.77% | 19.96% | 53.33 |
| AtriCure | 1.6B | - | 3.46 | -8.38% | -7.95% | 17.03 |
| Azenta | 1.5B | -10.80 | 0.90 | -8.58% | -9.77% | 3.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.